1
|
Wang Z, Hu Y, Wei S. The complete chloroplast genome of Ardisia brevicaulis Diels 1900, one traditional medicinal plant in southern China. Mitochondrial DNA B Resour 2023; 8:95-99. [PMID: 36643808 PMCID: PMC9833397 DOI: 10.1080/23802359.2022.2161326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
The complete chloroplast (cp) genome of Ardisia brevicaulis Diels 1900, one traditionally medicinal plant usually used in southern China, was first assembled and reported in this study. The genome size is 156,742 bp (37.1% GC content), containing a large single-copy (LSC) region of 86,329 bp, a small single-copy (SSC) region of 18,417 bp, and a pair of inverted repeat regions (IRs) of 25,998 bp. 134 genes (89 protein-coding, 37 tRNA, and 8 rRNA genes) are annotated in the whole cp genome, including 115 unique genes (81 protein-coding, 30 tRNA, and 4 rRNA genes). Phylogenetic analysis showed that A. brevicaulis is closely related to A. primulifolia and A. villosa, indicating their close phylogenetic relationship. The cp genome of A. brevicaulis could provide valuable genomic information for the phylogeny, molecular identification and discovery of new medicinal plant resources in Ardisia Swartz 1788.
Collapse
Affiliation(s)
- Zhiwei Wang
- College of Pharmacy, Germplasm Resources Development and Cultivation Technology Research Center of Guizhou Genuine Medicinal Materials Ganoderma lucidum, Guizhou University of Traditional Chinese Medicine, Guiyang, China,CONTACT Zhiwei Wang College of Pharmacy, Germplasm Resources Development and Cultivation Technology Research Center of Guizhou Genuine Medicinal Materials Ganoderma lucidum, Guizhou University of Traditional Chinese Medicine, Guiyang, China
| | - Youqiong Hu
- College of Pharmacy, Germplasm Resources Development and Cultivation Technology Research Center of Guizhou Genuine Medicinal Materials Ganoderma lucidum, Guizhou University of Traditional Chinese Medicine, Guiyang, China
| | - Shenghua Wei
- College of Pharmacy, Germplasm Resources Development and Cultivation Technology Research Center of Guizhou Genuine Medicinal Materials Ganoderma lucidum, Guizhou University of Traditional Chinese Medicine, Guiyang, China
| |
Collapse
|
2
|
Liu B, Liu R, Liu Q, Ashby CR, Zhang H, Chen ZS. The ethnomedicinal and functional uses, phytochemical and pharmacology of compounds from Ardisia species: An updated review. Med Res Rev 2022; 42:1888-1929. [PMID: 35670013 DOI: 10.1002/med.21894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2021] [Revised: 02/20/2022] [Accepted: 05/04/2022] [Indexed: 11/09/2022]
Abstract
Medicinal plants are considered to be a critical source of novel compounds and pharmacophores. The genus Ardisia, consisting of approximately 500 species, is the largest genus in the Myrsinaceae family. Ardisia species are widely distributed throughout tropical and subtropical regions of the world and have been used for the treatment of cancer, hypertension, irregular menstruation, gonorrhea, diarrhea and postnatal syndromes, among others. Phytochemical studies of Ardisia species have resulted in the isolation and identification of 111 compounds, including triterpenoid saponins, quinones, phenols, coumarins, cyclic depsipepetide and flavonoids. Crude extracts and isolates from Ardisia have been reported to have in vitro and in vivo efficacies, including but not limited to anticancer, antiinflammatory, antimicrobial, antioxidant, antithrombotic and antidiabetic, antitubercular compounds. This review focuses on the medical and functional uses, phytochemical profile and pharmacological efficacies of Ardisia species over the past 15 years. This review will provide information indicating that Ardisia species represent an invaluable source of potential therapeutic compounds.
Collapse
Affiliation(s)
- Bingrui Liu
- School of Public Health, North China University of Science and Technology, Tangshan, China.,College of Chemistry and Technology, Hebei Agricultural University, Huanghua, China
| | - Rongyu Liu
- Engineering Research Center for Medicine, College of Pharmacy, Harbin University of Commerce, Harbin, China
| | - Qifeng Liu
- College of Chemistry and Technology, Hebei Agricultural University, Huanghua, China
| | - Charles R Ashby
- Department of Pharmaceutical Sciences, St. John's University, New York City, New York, USA
| | - Hang Zhang
- Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety, and School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
| | - Zhe-Sheng Chen
- Department of Pharmaceutical Sciences, St. John's University, New York City, New York, USA
| |
Collapse
|
3
|
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung TN, Qu Z, Chen Z, Adelson DL, Lin L. Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy. Cytometry A 2019; 97:70-77. [PMID: 31411813 PMCID: PMC7004076 DOI: 10.1002/cyto.a.23869] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 05/21/2019] [Accepted: 07/01/2019] [Indexed: 12/27/2022]
Abstract
High incidence and mortality rates for non-small-cell lung cancer (NSCLC) lead to low survival rates. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are commonly first prescribed for NSCLC patients with EGFR mutations. However, most patients with sensitizing EGFR mutations become resistant to EGFR-TKI after 9-13 months treatment. Yiqi Chutan Tang (YQCT) has been prescribed as a treatment to this issue for over 20 years. In this report, high-performance liquid chromatography (HPLC) analysis, flow cytometry, western blot analysis, and functional annotation analysis were applied to uncover the molecular mechanisms of YQCT. Our results show the application of YQCT reduces gefitinib-induced drug resistance, induces slight cell cycle arrest, enhances gefitinib-induced apoptosis, and activates the autophagy. These results indicate that at the molecular level YQCT can reduce drug resistance and improve anti-cancer effects when associated with gefitinib, which could be a result of enhancement of apoptosis and autophagy in the EGFR-TKI resistant cells of NSCLC. This research provides a new treatment strategy for patients with EGFR-TKI resistance in NSCLC. © 2019 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of International Society for Advancement of Cytometry.
Collapse
Affiliation(s)
- Jue Zhang
- First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong Province, China
| | - Lingling Sun
- First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong Province, China
| | - Jian Cui
- Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia
| | - Jing Wang
- First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong Province, China
| | - Xiaomin Liu
- Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong Province, China
| | - Thazin Nwe Aung
- Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia
| | - Zhipeng Qu
- Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia
| | - Zhuangzhong Chen
- First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong Province, China
| | - David L Adelson
- Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia
| | - Lizhu Lin
- First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong Province, China
| |
Collapse
|